Emcure Pharmaceuticals Ltd

NSE
EMCURE •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Emcure Pharmaceuticals Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W Low in past week
29.1
TTM PE Ratio
Price to Book Ratio
High in industry
7.9
Dividend yield 1yr %
0
TTM PEG Ratio
RSI
RSI is not available
MFI
MFI is not available

Emcure Pharmaceuticals Ltd shareholding Pattern

Promoter
78.1%
Foreign Institutions
1.8%
Mutual Funds
1.8%
Domestic Institutions
3.4%
Public
16.8%

Emcure Pharmaceuticals Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
2
5Day EMA
1,326.60
EMA
NaN
EMA
NaN
EMA
NaN
EMA
NaN
EMA
NaN
EMA
NaN
EMA
NaN
5Day SMA
1,337.80
SMA
NaN
SMA
NaN
SMA
NaN
SMA
NaN
SMA
NaN
SMA
NaN
SMA
NaN
Delivery & Volume
Resistance & Support
1,289.20
Pivot
Resistance
First Resistance
1,317.35
Second Resistance
1,351.55
Third Resistance
1,379.70
Support
First Support
1,255
Second support
1,226.85
Third Support
1,192.65
Relative Strength Index
0.00
Money Flow Index
0.00
MACD
0.00
MACD Signal
0.00
Average True Range
0.00
Average Directional Index
0.00
Rate of Change (21)
0.00
Rate of Change (125)
0.00
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Ajanta Pharma Ltd.
29403.03
1398.9
2540
J B Chemicals & Pharmaceuticals Ltd.
28329.49
1183.8
1940
Natco Pharma Ltd.
22564.26
724.2
1311
Pfizer Ltd.
23749.48
3800.1
5344
Syngene International Ltd.
30502.24
607.65
860.25
Laurus Labs Ltd.
23208.11
328.15
484.3

Emcure Pharmaceuticals Ltd Company background

Founded in: 1981
Managing director: SATISH RAMANLAL MEHTA
Emcure Pharmaceuticals Ltd. was originally incorporated as Emcure Pharmaceuticals Private Limited, as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited, through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.The Company is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Emcure Pharmas were ranked as the largest pharmaceutical company in India in the gynecology, blood related and HIV antivirals therapeutic areas. It has 14 manufacturing facilities across India, which are capable in producing pharmaceutical and biopharmaceutical products of dosage forms, including oral solids, oral liquids, injectables including lipid, liposomal, lyophilized injectables, biologics, vaccines and complex APIs, including chiral molecules and cytotoxic products. The Company keeps a strong track record in developing portfolios of differentiated products across several platforms, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far. In year 1999, Lasor Drugs Limited was amalgamated with the Company. Thereafter, Emcure Laboratories Private Limited., Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiraral Mehta Sales Private Limited were amalgamated with Company during period 2001. The Company established facility in Kurkumbh in 2006 and then commenced operations of injectables facility in Hinjawadi. The facility established by Companys Subsidiary, Gennova Biopharmaceuticals Limited at Hinjawadi was made operational.The Company started operations in solid orals at facility in Jammu in 2009. During 2012, it acquired rights of BiCNUr, a branded oncology product prescribed for treatment of brain tumors, multiple myeloma, Hodgkins disease and nonHodgkins lymphoma. Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018.The Company has a portfolio of six commercialized and inhouse manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase,commonly used for acute myocardial infraction, and the biosimilar for Pegylatedasparaginase, commonly used for treating patients with leukemia. It hold the global patent for use of Tenectaplase to treat Acute Ischemic Stroke as a second indication in 2021.The Company is proposing an Initial Public Offering of Rs 1100 Crore Equity Shares through Fresh Issue and an Offer for Sale upto 18,168,356 Equity Shares.
Read More

Emcure Pharmaceuticals Ltd FAQs

Emcure Pharmaceuticals Ltd shares are currently priced at 1301 on NSE and 1300.85 on BSE as of 7/23/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Emcure Pharmaceuticals Ltd [EMCURE] share was 0. The Emcure Pharmaceuticals Ltd [EMCURE] share hit a 1-year low of Rs. 1261.05 and a 1-year high of Rs. 1408.7.

The market cap of Emcure Pharmaceuticals Ltd is Rs. 24264.15 Cr. as of 7/23/2024 12:00:00 AM.

The PE ratios of Emcure Pharmaceuticals Ltd is 147.13 as of 7/23/2024 12:00:00 AM.

The PB ratios of Emcure Pharmaceuticals Ltd is 9.17 as of 7/23/2024 12:00:00 AM

The Mutual Fund Shareholding was 1.77% at the end of 7/23/2024 12:00:00 AM.

You can easily buy Emcure Pharmaceuticals Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -